2021-09-06
dr. aimin hui, president of fosun pharma global r&d, granted the 4th "china translational medicine award - international collaboration"
on september 5, the awarding ceremony of the 4th "china translational medicine award" was held in beijing. dr. aimin hui, fosun pharma's executive president, president of global r&d, and chief medical officer, was granted the 4th "china translational medicine award - international collaboration".
about fosun pharma
founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock code: 600196.sh, 02196.hk) is a global innovation-driven pharmaceutical and healthcare industry group deeply rooted in china with strategic layouts in the pharmaceutical and healthcare industrial chain. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm group co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. through independent r&d, cooperative development, license-in, and in-depth incubation, fosun pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy in such major disease areas as tumors, immunological diseases, 4 high health risks (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system diseases. moreover, fosun pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, rna, oncolytic virus and gene therapy to enhance its innovation ability.
looking forward, under the guidance of 4in strategy (innovation, internationalization, integration and intelligentization), fosun pharma strives to be a leading enterprise in the global pharmaceutical and healthcare markets by practicing the development model based on innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development.
for more information, please visit our official website: k8凯发-凯发k8国际。
about fosun pharma
founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock code: 600196.sh, 02196.hk) is a global innovation-driven pharmaceutical and healthcare industry group deeply rooted in china with strategic layouts in the pharmaceutical and healthcare industrial chain. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm group co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. through independent r&d, cooperative development, license-in, and in-depth incubation, fosun pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy in such major disease areas as tumors, immunological diseases, 4 high health risks (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system diseases. moreover, fosun pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, rna, oncolytic virus and gene therapy to enhance its innovation ability.
looking forward, under the guidance of 4in strategy (innovation, internationalization, integration and intelligentization), fosun pharma strives to be a leading enterprise in the global pharmaceutical and healthcare markets by practicing the development model based on innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development.
for more information, please visit our official website: k8凯发-凯发k8国际。
previous:2021 csco | henlius publishes phase ii clinical data of novel anti-pd-1 mab serplulimab for 'pan-cancer' treatment of msi-h solid tumors
next:han da yuan®(adalimumab injection) presented at the 27th national academic conference on dermatology and venereology of the chinese medical association